Oral LD50 Mouse : 16500 mg/kg. Side effects include moderate to severe erythema (redness) and moderate edema (raised kin), nausea, vomiting, headache, dizziness, and tiredness. Higher exposure causes unconsciousness.
An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Sulfacetamide. |
| Benzylpenicillin | Sulfacetamide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Sulfacetamide. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Sulfacetamide. |
| Insulin human | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin human. |
| Insulin lispro | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin lispro. |
| Insulin glargine | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin glargine. |
| Insulin pork | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin pork. |
| Insulin aspart | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin aspart. |
| Insulin detemir | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin detemir. |
| Insulin glulisine | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin glulisine. |
| NN344 | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with NN344. |
| Insulin beef | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin beef. |
| Insulin degludec | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin degludec. |
| Insulin argine | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin argine. |
| Insulin peglispro | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin peglispro. |
| Insulin tregopil | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin tregopil. |
| Chloroprocaine | The therapeutic efficacy of Sulfacetamide can be decreased when used in combination with Chloroprocaine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Benzocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Quinisocaine. |
| Cisatracurium | Sulfacetamide may increase the neuromuscular blocking activities of Cisatracurium. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Sulfacetamide. |
| Insulin icodec | The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin icodec. |